Radiopharm Theranostics Limited (AU:RAD) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Radiopharm Theranostics Limited has received approval from the Australian Ethics Committee to expand its Phase 1 trial of RAD204 to include five additional PD-L1 expressing solid tumor types. This expansion aims to evaluate the safety and efficacy of RAD204, a novel radioimmunotherapy, in treating advanced cancers with high unmet needs. The trial’s progress could position Radiopharm Theranostics as a key player in the innovative oncology radiopharmaceuticals market.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.